Northeast Financial Consultants’s Tango Therapeutics TNGX Stock Holding History

Northeast Financial Consultants’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$51.2K	Buy	+10,000	New	+$24.7K	﹤0.01%	297

Other funds holding TNGX

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Northeast Financial Consultants's TNGX Position: Q2 2025 in Review

Northeast Financial Consultants opened a new position in Tango Therapeutics (TNGX) in Q2 2025: 10,000 shares worth $51.2K. The stake represents ﹤0.01% of the portfolio and ranks #297 among its holdings.

115 funds tracked by Wall St. Rank hold TNGX as of Q2 2025.

Northeast Financial Consultants held 10,000 shares of Tango Therapeutics worth $51.2K as of Q2 2025.
Tango Therapeutics was a new Northeast Financial Consultants position in Q2 2025.
Tango Therapeutics made up ﹤0.01% of Northeast Financial Consultants's portfolio in Q2 2025, its #297 holding.
115 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2025.

Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.